Shares in Kalaris Therapeutics fell on Monday, declining 3.8% to 142p by midday trading, even as the biotech firm announced the appointment of a new chief financial officer. The move, intended to bolster investor confidence, failed to reverse a broader sell-off driven by persistent worries over the company's financial discipline and pipeline costs.
The FTSE 250-listed company named Sarah Mitchell as its new CFO, succeeding James Harding who departed last month. Mitchell joins from a rival pharmaceutical group and brings extensive experience in corporate finance and restructuring. In a statement, Kalaris said the appointment was part of a broader effort to strengthen its executive team amid a challenging period for the sector.
Despite the leadership change, market sentiment remained downbeat. Analysts at Peel Hunt noted that while a new CFO can help steady the ship, the underlying issues — including high cash burn from late-stage trials and uncertain revenue projections — have not been resolved. “Investors are looking for clearer signs of a path to profitability, not just a change in personnel,” the analysts said in a note.
The broader healthcare sector was mixed, with the FTSE 350 Health Care Index edging up 0.2%. However, Kalaris was one of the worst performers in the mid-cap index. Other notable movers included Hikma Pharmaceuticals, which rose 1.1%, and Dechra Pharmaceuticals, down 0.4%.
For UK investors and pension holders with exposure to mid-cap biotech, the decline underscores the volatility inherent in the sector. Kalaris remains a speculative holding for many retail investors, with its share price down over 20% year-to-date. The company is expected to provide a trading update in the coming weeks, which may offer more clarity on its financial trajectory.